Enhanced Antibacterial Activity of Repurposed Mitomycin C and Imipenem in Combination with the Lytic Phage vB_KpnM-VAC13 against Clinical Isolates of Klebsiella pneumoniae
Olga Pacios, Laura Fernández-García, Ines Bleriot, Lucía Blasco, Mónica González-Bardanca, María López, Felipe Fernández-Cuenca, Jesús Oteo, Álvaro Pascual, Luis Martínez-Martínez, Pilar Domingo-Calap, Germán Bou, María Tomás
Abstract
Klebsiella pneumoniae is an opportunistic Gram-negative pathogen that employs different strategies (resistance and persistence) to counteract antibiotic treatments. This study aimed to search for new means of combatting imipenem-resistant and persister strains of K. pneumoniae by repurposing the anticancer drug mitomycin C as an antimicrobial agent and by combining the drug and the conventional antibiotic imipenem with the lytic phage vB_KpnM-VAC13.
Topics & Concepts
Lytic cycleMicrobiologyKlebsiella pneumoniaeImipenemMitomycin CBiologyAntibioticsAntibacterial agentBroth microdilutionMyoviridaeVirologyEtestPseudomonas aeruginosaAntimicrobialDrug resistanceBacteriophageBacteriaAntibacterial activityCeftazidimeMultidrug toleranceAntibiotic Resistance in BacteriaBacteriophages and microbial interactionsMicrobial Natural Products and Biosynthesis